Stock PIII P3 HEALTH PARTNERS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials P3 Health Partners Inc.

Equities

PIII

US7444131053

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 11:47:29 2024-05-24 am EDT 		5-day change 1st Jan Change
0.614 USD +2.33% Intraday chart for P3 Health Partners Inc. -0.23% -57.23%
May. 22 P3 Health Partners Inc. announced that it expects to receive $42.2598 million in funding from Chicago Pacific Founders CI
May. 08 Earnings Flash (PIII) P3 HEALTH PARTNERS Reports Q1 Revenue $388.5M, vs. Street Est of $357.2M MT

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025
Capitalization 1 292.7 76.51 162.5 71.77 -
Enterprise Value (EV) 1 235.9 76.51 162.5 141.8 106.5
P/E ratio - -0.28 x -2.24 x -1.9 x -2.02 x
Yield - - - - -
Capitalization / Revenue 0.46 x 0.07 x 0.13 x 0.05 x 0.04 x
EV / Revenue 0.37 x 0.07 x 0.13 x 0.09 x 0.06 x
EV / EBITDA -2.47 x -0.6 x -1.9 x -33 x 4.42 x
EV / FCF - -0.57 x - 7.75 x 2.77 x
FCF Yield - -175% - 12.9% 36.1%
Price to Book - - - 0.57 x 0.64 x
Nbr of stocks (in thousands) 41,579 41,579 115,242 119,620 -
Reference price 2 7.040 1.840 1.410 0.6000 0.6000
Announcement Date 10/21/22 3/31/23 3/28/24 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Net sales 1 - 637.4 1,050 1,266 1,525 1,739
EBITDA 1 - -95.49 -127.9 -85.5 -4.296 24.08
EBIT 1 - -187.9 -1,561 -167.9 -94.94 -78.06
Operating Margin - -29.49% -148.73% -13.26% -6.22% -4.49%
Earnings before Tax (EBT) 1 - - -1,560 -183.7 -113.5 -94.83
Net income 1 -41.07 - -270.1 -57.77 -19.93 4.709
Net margin - - -25.74% -4.56% -1.31% 0.27%
EPS 2 -0.6200 - -6.500 -0.6300 -0.3150 -0.2967
Free Cash Flow 1 - - -133.8 - 18.3 38.4
FCF margin - - -12.74% - 1.2% 2.21%
FCF Conversion (EBITDA) - - - - - 159.47%
FCF Conversion (Net income) - - - - - 815.46%
Dividend per Share - - - - - -
Announcement Date 8/12/21 10/21/22 3/31/23 3/28/24 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 177.9 273.5 269.5 248.3 258.2 302.1 329.1 288.4 346.9 388.5 388 359.2 389.9 430.7 435.8
EBITDA 1 -43.05 -18.93 -28.6 -40.31 -40.1 -19.13 0.217 -22.33 -44.26 -19.77 -2.576 9.201 12.69 -6.22 10.98
EBIT 1 -127.4 -52.17 -912.2 -60.01 -536.5 -48.82 -21.03 -33.82 -64.26 -43.83 -26.21 -15.64 -12.51 - -
Operating Margin -71.63% -19.07% -338.53% -24.17% -207.78% -16.16% -6.39% -11.73% -18.53% -11.28% -6.76% -4.35% -3.21% - -
Earnings before Tax (EBT) 1 - - - -65.33 -530.5 -52.16 -27.36 -36.88 -67.34 -47.53 -30.71 -17.94 -17.51 - -
Net income 1 - - - -11.17 -94 -9.199 -9.816 -13.3 -25.46 -18.7 -0.1115 -0.042 -1.077 - -
Net margin - - - -4.5% -36.41% -3.05% -2.98% -4.61% -7.34% -4.81% -0.03% -0.01% -0.28% - -
EPS 2 - - - -0.2700 -2.260 -0.2200 -0.0900 -0.1200 -0.2200 -0.1600 -0.1050 -0.0350 -0.0267 -0.1600 -0.1300
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 10/21/22 10/21/22 10/20/22 11/14/22 3/31/23 5/10/23 8/7/23 11/8/23 3/28/24 5/8/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Net Debt 1 - - - - 70 34.7
Net Cash position 1 - 56.9 - - - -
Leverage (Debt/EBITDA) - - - - -16.29 x 1.441 x
Free Cash Flow 1 - - -134 - 18.3 38.4
ROE (net income / shareholders' equity) - - - - - -
ROA (Net income/ Total Assets) - - - - - -
Assets 1 - - - - - -
Book Value Per Share 2 - - - - 1.050 0.9400
Cash Flow per Share 2 - -1.680 -3.030 - 0.1900 0.3700
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 8/12/21 10/21/22 3/31/23 3/28/24 - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for P3 Health Partners Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
0.6 USD
Average target price
2.7 USD
Spread / Average Target
+350.00%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
P3 HEALTH PARTNERS INC. Stock P3 Health Partners Inc.
-61.35% 71.77M
MODERNA, INC. Stock Moderna, Inc.
+68.91% 62.86B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.18% 41.38B
LONZA GROUP AG Stock Lonza Group AG
+45.26% 40.38B
CELLTRION, INC. Stock Celltrion, Inc.
-8.93% 27.64B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.80% 26.46B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.90% 18.9B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+4.43% 12.67B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.79% 12.27B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.73% 12.07B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. PIII Stock
  4. Financials P3 Health Partners Inc.